UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040854
Receipt number R000046646
Scientific Title Effects of Metformin on Japanese type 2 diabetes patients: a retrospective study: METRO study
Date of disclosure of the study information 2020/06/23
Last modified on 2020/06/22 17:24:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of Metformin on Japanese type 2 diabetes patients: a retrospective study: METRO study

Acronym

Effects of Metformin on Japanese type 2 diabetes patients: a retrospective study: METRO study

Scientific Title

Effects of Metformin on Japanese type 2 diabetes patients: a retrospective study: METRO study

Scientific Title:Acronym

Effects of Metformin on Japanese type 2 diabetes patients: a retrospective study: METRO study

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We examine that the therapeutic effects of metformin after 24 weeks in patients with type 2 diabetes who were prescribed metformin due to the difference in the timing of the introduction of metformin.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The change in HbA1c decrease due to differences in metformin introduction timing (1st, 2nd, 3rd, 4th and later).

Key secondary outcomes

We compare the changes in body weight, biochemical examination, and incidence of adverse events at the time of introduction and at 24 weeks with the difference in the timing of Metformin introduction.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1)Patients with type 2 diabetes who were newly prescribed metformin from January 1, 2008 to November 30, 2019 and can be followed by a 24-week observation period(January 1, 2008-May 20, 2020).
2)Patients who have not stopped/changed/added hypoglycemic agents other than metformin during the 24-week observation period(Regarding insulin, the number of units can be changed and canceled).
3)Patients who have not changed or discontinued other antidiabetic drugs at the timing of introducing metformin.

Key exclusion criteria

1)Patients with type 1 diabetes or secondary diabetes.
2)Patients whose other diabetes drugs are changed, increased, or discontinued at the same time as the start of metformin administration.
3) Patients who are changing diabetes drugs other than metformin (including changing the dose) during the 24-week observation period (changes in the number of insulin units can be incorporated).
4) Patients who are judged to have extremely poor medication compliance based on medical records.
5) Patients with steroid (oral/injection) treatment.
6) Patients with cancer (can be included if they are in follow-up during remission).
7) Patients who were hospitalized during the observation period.
8) Patients with severe infections and trauma.
9) Patients who are judged to be inappropriate as a subject by the doctor's judgment.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Tadashi
Middle name
Last name Yamakawa

Organization

Yokohama City University Medical Center

Division name

Department of Endocrinology and Diabetes

Zip code

2320024

Address

4-57 Urafune-cho, Mimami-ku, Yokohama City, 232-0024, Japan

TEL

0452615656

Email

naibunpi@urahp.yokohama-cu.ac.jp


Public contact

Name of contact person

1st name MARINA
Middle name
Last name HARADA

Organization

Yokohama City University Medical Center

Division name

Department of Endocrinology and Diabetes

Zip code

2320024

Address

4-57 Urafune-cho, Mimami-ku, Yokohama City, 232-0024, Japan

TEL

09053294853

Homepage URL


Email

onyogora@yokohama-cu.ac.jp


Sponsor or person

Institute

Yokohama City University Medical Center

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Yokohama City University Public University Corporation Medical Research Ethics Committee for Humans

Address

3-9 Fukuura, Kanazawa-ku, Yokohama-shi, Kanagawa

Tel

0453707627

Email

rinri@yokohama-cu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

横浜市立大学附属市民総合医療センター
浦舟金沢内科クリニック


Other administrative information

Date of disclosure of the study information

2020 Year 06 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2020 Year 04 Month 01 Day

Date of IRB

2020 Year 06 Month 18 Day

Anticipated trial start date

2020 Year 06 Month 18 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

We analyze the factors that influence the effect of metformin


Management information

Registered date

2020 Year 06 Month 22 Day

Last modified on

2020 Year 06 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046646


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name